These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 24311736)

  • 1. Expectations and experiences of investigators and parents involved in a clinical trial for Duchenne/Becker muscular dystrophy.
    Peay HL; Tibben A; Fisher T; Brenna E; Biesecker BB
    Clin Trials; 2014 Feb; 11(1):77-85. PubMed ID: 24311736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Watching time tick by…": Decision making for Duchenne muscular dystrophy trials.
    Peay HL; Scharff H; Tibben A; Wilfond B; Bowie J; Johnson J; Nagaraju K; Escolar D; Piacentino J; Biesecker BB
    Contemp Clin Trials; 2016 Jan; 46():1-6. PubMed ID: 26546066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Barriers and facilitators to clinical trial participation among parents of children with pediatric neuromuscular disorders.
    Peay HL; Biesecker BB; Wilfond BS; Jarecki J; Umstead KL; Escolar DM; Tibben A
    Clin Trials; 2018 Apr; 15(2):139-148. PubMed ID: 29475375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expectations and anxieties of Duchenne muscular dystrophy patients and their families during the first-in-human clinical trial of NS-065/NCNP-01.
    Shimizu R; Ohata M; Tachimori H; Kimura E; Harada Y; Takeshita E; Tamaura A; Takeda S; Komaki H
    Brain Dev; 2020 Apr; 42(4):348-356. PubMed ID: 31992520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An intervention to improve the quality of life in children of parents with serious mental illness: the Young SMILES feasibility RCT.
    Abel KM; Bee P; Gega L; Gellatly J; Kolade A; Hunter D; Callender C; Carter LA; Meacock R; Bower P; Stanley N; Calam R; Wolpert M; Stewart P; Emsley R; Holt K; Linklater H; Douglas S; Stokes-Crossley B; Green J
    Health Technol Assess; 2020 Nov; 24(59):1-136. PubMed ID: 33196410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An Evidence-Based, Community-Engaged Approach to Develop an Interactive Deliberation Tool for Pediatric Neuromuscular Trials.
    Moultrie RR; Lewis MA; Paquin RS; Lucas A; Jarecki J; Peay HL
    J Genet Couns; 2018 Apr; 27(2):416-425. PubMed ID: 29260486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the experiences of lung volume recruitment among boys with Duchenne muscular dystrophy: A multicenter qualitative study.
    Katz SL; Blinder H; Newhook D; Bmus LA; Nicholls S; McMillan HJ; Mah JK; Campbell C; McAdam LC; Zielinski D; Toupin-April K; Momoli F; McKim DA
    Pediatr Pulmonol; 2023 Jan; 58(1):46-54. PubMed ID: 36102618
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Engaging Participants in Rare Disease Research: A Qualitative Study of Duchenne Muscular Dystrophy.
    Bendixen RM; Morgenroth LP; Clinard KL
    Clin Ther; 2016 Jun; 38(6):1474-1484.e2. PubMed ID: 27136712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Psychosocial Needs and Facilitators of Mothers Caring for Children with Duchenne/Becker Muscular Dystrophy.
    Peay HL; Meiser B; Kinnett K; Tibben A
    J Genet Couns; 2018 Feb; 27(1):197-203. PubMed ID: 28803420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parental perspectives on the diagnostic process for Duchenne and Becker muscular dystrophy.
    Daack-Hirsch S; Holtzer C; Cunniff C
    Am J Med Genet A; 2013 Apr; 161A(4):687-95. PubMed ID: 23494880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 'We knew it was a totally at random thing': parents' experiences of being part of a neonatal trial.
    Harvey M; Nongena P; Edwards D; Redshaw M
    Trials; 2017 Aug; 18(1):361. PubMed ID: 28764800
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uncertainty, hope, and coping efficacy among mothers of children with Duchenne/Becker muscular dystrophy.
    Bell M; Biesecker BB; Bodurtha J; Peay HL
    Clin Genet; 2019 Jun; 95(6):677-683. PubMed ID: 30847900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aquatic therapy for children with Duchenne muscular dystrophy: a pilot feasibility randomised controlled trial and mixed-methods process evaluation.
    Hind D; Parkin J; Whitworth V; Rex S; Young T; Hampson L; Sheehan J; Maguire C; Cantrill H; Scott E; Epps H; Main M; Geary M; McMurchie H; Pallant L; Woods D; Freeman J; Lee E; Eagle M; Willis T; Muntoni F; Baxter P
    Health Technol Assess; 2017 May; 21(27):1-120. PubMed ID: 28627356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Parental Reflections on the Diagnostic Process for Duchenne Muscular Dystrophy: A Qualitative Study.
    Bendixen RM; Houtrow A
    J Pediatr Health Care; 2017; 31(3):285-292. PubMed ID: 27743907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Parents' perspectives on coping with Duchenne muscular dystrophy.
    Webb CL
    Child Care Health Dev; 2005 Jul; 31(4):385-96. PubMed ID: 15948875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient engagement in clinical trial design for rare neuromuscular disorders: impact on the DELIVER and ACHIEVE clinical trials.
    Furlong P; Dugar A; White M
    Res Involv Engagem; 2024 Jan; 10(1):1. PubMed ID: 38167117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A survey of the feasibility of developing osteoporosis clinical trials in Duchenne muscular dystrophy: Survey of the opinion of young people with Duchenne muscular dystrophy, families and clinicians.
    Choong Wong S; Joseph S; Capaldi N; Marco MD; Dunne J; Guglieri M; Horrocks I; Straub V; Faisal Ahmed S;
    Clin Trials; 2021 Feb; 18(1):39-50. PubMed ID: 33012180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Parents' Reactions to the Diagnosis of Duchenne Muscular Dystrophy: Associations Between Resolution, Family Functioning, and Child Behavior Problems.
    Baiocco R; Castelli Gattinara P; Cioccetti G; Ioverno S
    J Nurs Res; 2017 Dec; 25(6):455-463. PubMed ID: 29099477
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
    McDonald CM; Campbell C; Torricelli RE; Finkel RS; Flanigan KM; Goemans N; Heydemann P; Kaminska A; Kirschner J; Muntoni F; Osorio AN; Schara U; Sejersen T; Shieh PB; Sweeney HL; Topaloglu H; Tulinius M; Vilchez JJ; Voit T; Wong B; Elfring G; Kroger H; Luo X; McIntosh J; Ong T; Riebling P; Souza M; Spiegel RJ; Peltz SW; Mercuri E; ;
    Lancet; 2017 Sep; 390(10101):1489-1498. PubMed ID: 28728956
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complementary and alternative medicine for Duchenne and Becker muscular dystrophies: characteristics of users and caregivers.
    Zhu Y; Romitti PA; Conway KM; Andrews J; Liu K; Meaney FJ; Street N; Puzhankara S; Druschel CM; Matthews DJ
    Pediatr Neurol; 2014 Jul; 51(1):71-7. PubMed ID: 24785967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.